2023
Expression of cancer–testis antigens in the immune microenvironment of non‐small cell lung cancer
Hikmet F, Rassy M, Backman M, Méar L, Mattsson J, Djureinovic D, Botling J, Brunnström H, Micke P, Lindskog C. Expression of cancer–testis antigens in the immune microenvironment of non‐small cell lung cancer. Molecular Oncology 2023, 17: 2603-2617. PMID: 37341056, PMCID: PMC10701773, DOI: 10.1002/1878-0261.13474.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerCancer-testis antigensCell lung cancerImmune microenvironmentLung cancerT cellsCTA expressionAnti-cancer immune responseMost NSCLC casesEfficacy of immunotherapyPlasma cell infiltrationRegulatory T cellsImmune cell densityCellular immune reactionsNSCLC patientsImmune profileClinical outcomesNSCLC casesCell infiltrationImmune cellsImmunohistochemical profilingM2 macrophagesClinical dataImmune responseImmune reactions
2019
Multiplex plasma protein profiling identifies novel markers to discriminate patients with adenocarcinoma of the lung
Djureinovic D, Pontén V, Landelius P, Al Sayegh S, Kappert K, Kamali-Moghaddam M, Micke P, Ståhle E. Multiplex plasma protein profiling identifies novel markers to discriminate patients with adenocarcinoma of the lung. BMC Cancer 2019, 19: 741. PMID: 31357969, PMCID: PMC6664554, DOI: 10.1186/s12885-019-5943-3.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinoma of LungAgedBlood ProteinsCarcinoembryonic AntigenCarcinoma, Non-Small-Cell LungChemokines, CXCCohort StudiesData AccuracyEarly Detection of CancerFemaleGPI-Linked ProteinsHumansImmunoassayLung NeoplasmsMaleMass ScreeningModels, BiologicalReceptor, ErbB-3ROC CurveSensitivity and SpecificityStatistics, NonparametricVascular Endothelial Growth Factor Receptor-2ConceptsNon-small cell lung cancerProximity extension assayLung adenocarcinomaLung diseaseDisease groupNon-malignant lung diseasesEarly lung cancer detectionCell lung cancerDifferent lung diseasesDifferent plasma levelsMultiplex proximity extension assayHigh clinical relevanceNovel protein markersDifferent plasma concentrationsLocalized diseaseOverall prognosisSurgical resectionNSCLC patientsLung metastasesColorectal cancerLung cancerPlasma levelsTypical carcinoidLung conditionsLAC patientsPrognostic Impact of Tumor Cell Programmed Death Ligand 1 Expression and Immune Cell Infiltration in NSCLC
Edlund K, Madjar K, Mattsson J, Djureinovic D, Lindskog C, Brunnström H, Koyi H, Brandén E, Jirström K, Pontén F, Rahnenführer J, Micke P, Hengstler J. Prognostic Impact of Tumor Cell Programmed Death Ligand 1 Expression and Immune Cell Infiltration in NSCLC. Journal Of Thoracic Oncology 2019, 14: 628-640. PMID: 30639618, DOI: 10.1016/j.jtho.2018.12.022.Peer-Reviewed Original ResearchConceptsPD-L1 positivityOverall survivalLymphocyte infiltrationSmoking historyPD-L1Prognostic associationPlasma cellsProgrammed Death Ligand 1 ExpressionTumor PD-L1 positivityDeath ligand 1 (PD-L1) expressionAssociation of lymphocytePositive immune cellsLigand 1 expressionPD-L1 axisPD-L1 statusMultivariate Cox regressionDeath ligand 1Longer overall survivalForkhead box P3Immune cell infiltrationShorter overall survivalPatients' smoking historyKaplan-Meier plotsCheckpoint inhibitorsNSCLC patients
2018
Detection of autoantibodies against cancer-testis antigens in non-small cell lung cancer
Djureinovic D, Dodig-Crnković T, Hellström C, Holgersson G, Bergqvist M, Mattsson J, Pontén F, Ståhle E, Schwenk J, Micke P. Detection of autoantibodies against cancer-testis antigens in non-small cell lung cancer. Lung Cancer 2018, 125: 157-163. PMID: 30429015, DOI: 10.1016/j.lungcan.2018.09.012.Peer-Reviewed Original ResearchConceptsCancer-testis antigensLung cancer patientsNSCLC patientsCancer patientsNon-small cell lung cancer patientsNon-small cell lung cancerCell lung cancer patientsLin-28 homolog BPresence of autoantibodiesCell lung cancerBenign lung diseasesDetection of autoantibodiesFamily member 3Immune targetsLung diseaseLung cancerNSCLC samplesImmune responseAutoantibodiesBenign groupPatientsBead arrayBead array technologyAntigenMember A (Fam46a) gene
2017
PD-L1 immunohistochemistry in clinical diagnostics: Inter-pathologist variability is as high as assay variability.
Micke P, Johansson A, Westbom-Fremer A, Backman M, Djureinovic D, Patthey A, Isaksson-Mettävainio M, Gulyas M, Brunnstrom H. PD-L1 immunohistochemistry in clinical diagnostics: Inter-pathologist variability is as high as assay variability. Journal Of Clinical Oncology 2017, 35: e20637-e20637. DOI: 10.1200/jco.2017.35.15_suppl.e20637.Peer-Reviewed Original ResearchNon-small cell lung cancerTissue microarrayPositive casesInter-rater variabilityTumor cell membrane stainingTumor cellsPD-L1 assaysPD-L1 expressionPD-L1 immunohistochemistryCell lung cancerPD-L1 scoresPositive tumor cellsTumor cell stainingSP142 cloneCheckpoint inhibitorsCell membrane stainingNSCLC patientsLung cancerTherapy responseClone 28Available drugsInter-pathologist variabilitySix-grade scaleClinical situationsSP263